Financial Data and Key Metrics Changes - In 2022, the company's sales revenue decreased by 20% to 1.318 billion [3][4] - The net profit margin remained at 13%, with a net profit margin of 17.1% [4][5] - The overall profit contribution decreased by 35%, amounting to a decline of 225 million [4][5] Business Line Data and Key Metrics Changes - Revenue from the ophthalmology segment was 554 million, contributing a profit of 160 million, while the surgical segment generated 764 million in revenue with a profit contribution of 191 million [4][5] - The ophthalmology segment accounted for 42% of total revenue, while the surgical segment made up 58%, with ophthalmology increasing by one percentage point from the previous year [4][5] Market Data and Key Metrics Changes - The market share in the ophthalmology production factor sector reached 70.5%, up from 62.4% in 2021, an increase of 8.1 percentage points [3][4] - The company maintained a leading position in the global production factor market with a market share of 38.7%, up from 35% the previous year [3][4] Company Strategy and Development Direction - The company aims to become a leader in the ophthalmology and surgical adhesive markets, focusing on innovation and expanding its product portfolio [2][3] - The company has a mature industrial operation platform and a complete industrial chain from R&D to sales, which supports its growth potential [3][4] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in future growth despite the challenges posed by the pandemic, highlighting strong market demand and supportive government policies in the ophthalmology sector [4][5] - The company plans to continue investing in R&D, with a reported expenditure of 343 million HKD in 2022, representing a 65% increase year-on-year [4][5] Other Important Information - The company completed the acquisition of Sulisun, enhancing its core product offerings [5][6] - The company received multiple accolades, including being listed among the top 200 small and medium enterprises and the top 10 manufacturing companies in Zhuhai [6][7] Q&A Session All Questions and Answers Question: What are the company's future growth prospects? - The company remains optimistic about growth in the ophthalmology and surgical markets, with a focus on innovative treatments and expanding its product lines [4][5] Question: How has the pandemic affected the company's performance? - The pandemic has led to a 20% decline in sales revenue, but management believes the market demand remains strong and is expected to recover [4][5]
亿胜生物科技(01061) - 2022 Q4 - 业绩电话会